RT @ESHaematology: 📣 CHECK OUT THE MAIN SCIENTIFIC TOPICS OF #ESHMM2025! Learn more and register here ➡ 5th How to…

RT @RahulBanerjeeMD: CEPHEUS out! 👏 @szusmani et al. PFS ⬆️ ⬆️ with quad in ø ASCT #MMsm. Nice discussion of similarities (many) & differe…

RT @CancerNetwrk: Panelists discuss how emerging therapies like bispecific antibodies, CAR T cells, and novel drug combinations are reshapi…

RT @ESHaematology: ⌛️#ESHMM2025 THE DEADLINE TO SUBMIT IS TONIGHT AT 23:59 CET! Last chance: PROCEED NOW ➡ 5th How…

RT @CancerNetwrk: Efficacy results from the trial reveal that at a median follow-up of 50 months (range, 8-61) the primary end point of pro…

Daratumumab paves the way for early intervention in HR-SMM @IrenemGhobrial #mmsm

RT @IrenemGhobrial: @OmarNadeemMD @DanaFarber The data also demonstrates that WGS can inform genomic changes in SMM beyond cytogenetics and…

RT @IrenemGhobrial: @OmarNadeemMD @DanaFarber The study demonstrates that depth of response matters in high risk smoldering myeloma and bui…

Our I-PRISM trial of Ixa/Len/Dex in HR-SMM demonstrates that depth of response predicts better outcomes in HR-SMM. Pts with CR and MRD neg disease had lower risk of SLIM-CRAB and biochemical PD⁦. ⁦@IrenemGhobrial Michelle Aranha ⁦@DanaFarber⁩

@JoshuaRichterMD @andrew02114 @DrOlaLandgren @JKaufmanMD @DrKrinaPatel Rarely unless very elderly/frail. In that case, daratumumab is a great option with low dose len

RT @ESHaematology: 📣 THE DEADLINE TO SUBMIT YOUR ABSTRACT FOR #ESHMM2025 IS APPROACHING: Jan. 15th Proceed now ➡ 5t…

RT @oncodaily: ‼️Highlights from ASH 2024 by @RahulBanerjeeMD ASH 2024 showcased groundbreaking advancements in hematology, with Rahul Ba…

RT @ESHaematology: 📣 #ESHMM2025 MEET THE CONFIRMED SPEAKERS TO DATE! Register & submit your abstract here ➡ 5th How…

@IrenemGhobrial @betsyodonnellmd @mvmateos @SagarLonialMD ++ many others working on precursor disease!

RT @IrenemGhobrial: Pangea 2.0 risk stratification in >2000 smoldering MM. thanks to all our collaborators. We can predict progression earl…

Phase II trial of Ixazomib, Lenalidomide and Dexamethasone in HR-SMM presented at #EHA2024 55 patients enrolled ORR 93%, CR 31% Median biochemical PFS of 49 months VGPR or greater correlated with improved PFS @IreneGhobrial @DanaFarber #mmsm

First results of BMS-986393 GPRC5D CAR T-Cells in 1-3 prior lines of therapy presented at #EHA2024 ORR 96%, CR 42% Low rates of dysgeusia/nail/skin changes 55% triple class refractory pts, 29% EMD Median 2 prior lines of therapy 87% of responses ongoing #mmsm

RT @power4patients: What are bispecific antibodies, and how are they advancing #myeloma care? @OmarNadeemMD of @danafarber explains. https:…

RT @VincentRK: The perspective comments on real world data published in @BloodCancerJnl by @AimazAfrough @YiLinMDPhD @SurbhiSidanaMD @GKaur…